TACR1 and attention deficit-hyperactivity disorder: While further testing is necessary to assess the therapeutic potential of these drugs and the clinical relevance of TACR1 polymorphisms, the 5C-CPT demonstrates considerable utility in the context of preclinical ADHD research.